Clinical trial
Sirolimus in Treating Patients With Glioblastoma Multiforme
NCT00047073 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00047073 |
|---|---|
| Title | Sirolimus in Treating Patients With Glioblastoma Multiforme |
| Official title | A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Procedure |
| Interventions | Rapamycin, Surgery, Supportive Care |
| Enrollment | 13 |
| Start date | Jul 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: